Bisdehydrodoisynolic acid

Edit links
From Wikipedia, the free encyclopedia
Bisdehydrodoisynolic acid
Identifiers
  • 1-Ethyl-7-hydroxy-2-methyl-1,2,3,4-tetrahydrophenanthrene-2-carboxylic acid
PubChem CID
UNII
Chemical and physical data
FormulaC18H20O3
Molar mass284.355 g·mol−1
3D model (JSmol)
  • CCC1C2=C(CCC1(C)C(O)=O)C1=CC=C(O)C=C1C=C2
  • InChI=1/C18H20O3/c1-3-16-15-6-4-11-10-12(19)5-7-13(11)14(15)8-9-18(16,2)17(20)21/h4-7,10,16,19H,3,8-9H2,1-2H3,(H,20,21)
  • Key:HMYBVYBHZVQZNH-UHFFFAOYNA-N

Bisdehydrodoisynolic acid (BDDA), as the (Z)-isomer ((Z)-BDDA), is a synthetic, nonsteroidal estrogen related to doisynolic acid that was never marketed.[1] It is one of the most potent estrogens known,[2][3] although it has more recently been characterized as a selective estrogen receptor modulator (SERM).[3][4] BDDA and other doisynolic acid derivatives display relatively low affinity accompanied by disproportionately high estrogenic potency in vivo,[5] which was eventually determined to be due to transformation into metabolites with greater estrogenic activity.[4] The drug was discovered in 1947 as a degradation product of the reaction of equilenin or dihydroequilenin with potassium hydroxide.[6] It is the seco-analogue of equilenin, while doisynolic acid is the seco-analogue of estrone.[7] These compounds, along with diethylstilbestrol, can be considered to be open-ring analogues of estradiol.[8] The methyl ether of BDDA, doisynoestrol, is also an estrogen, and in contrast to BDDA, has been marketed.[2][9]

See also[edit]

References[edit]

  1. ^ Banz W, Strader A, Ajuwon K, Ortiz L, James B, Higginbotham DA, Hou Y, Meyers C (May 2007). "The Effects of (+)-Z-bisdehydrodoisynolic Acid on Diabetic Phenotype in Female Obese Zucker Rats". Experimental Biology. pp. 17–. ISBN 978-0-549-22172-2.[permanent dead link]
  2. ^ a b Johnson WS, Graber RP (1950). "The Stobbe Condensation with 6-Methoxy-2-propionylnaphthalene. A Synthesis of Bisdehydrodoisynolic Acid1". Journal of the American Chemical Society. 72 (2): 925–935. doi:10.1021/ja01158a075. ISSN 0002-7863.
  3. ^ a b Blickenstaff RT, Ghosh AC, Wolf GC (22 October 2013). Total Synthesis of Steroids: Organic Chemistry: A Series of Monographs. Elsevier Science. pp. 63–. ISBN 978-1-4832-1642-3.
  4. ^ a b Adler M, Hou Y, Sandrock P, Meyers CY, Winters TA, Banz WJ, Adler S (August 2006). "Derivatives of Z-bisdehydrodoisynolic acid provide a new description of the binding-activity paradox and selective estrogen receptor modulator activity". Endocrinology. 147 (8): 3952–3960. doi:10.1210/en.2006-0316. PMID 16709609.
  5. ^ Banz WJ, Winters TA, Hou Y, Adler S, Meyers CY (December 1998). "Comparative effects of the selective estrogen receptor modulators (-)-, (+)- and (+/-)-Z bisdehydrodoisynolic acids on metabolic and reproductive parameters in male and female rats". Hormone and Metabolic Research. 30 (12): 730–736. doi:10.1055/s-2007-978968. PMID 9930631.
  6. ^ Pincus G, Thimann KV (2 December 2012). The Hormones V1: Physiology, Chemistry and Applications. Elsevier. pp. 364–366. ISBN 978-0-323-14206-9.
  7. ^ Journal of Scientific & Industrial Research. Council of Scientific & Industrial Research. 1984. p. 213.
  8. ^ Morice C, Wermuth CG (2 May 2011). "Ring transformations". In Wermuth CG (ed.). The Practice of Medicinal Chemistry. Academic Press. pp. 343-362 (344). ISBN 978-0-08-056877-5.
  9. ^ Elks J (14 November 2014). "Doisynoestrol". The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 465–. ISBN 978-1-4757-2085-3.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Bisdehydrodoisynolic_acid&oldid=1179978108"